Managing Raw Materials in the QbD Paradigm, Part 2: Risk Assessment and Communication - Evaluate and communicate risk to stakeholders. - BioPharm International

ADVERTISEMENT

Managing Raw Materials in the QbD Paradigm, Part 2: Risk Assessment and Communication
Evaluate and communicate risk to stakeholders.


BioPharm International


CONCLUSIONS

This article presents an approach for managing raw materials in the QbD paradigm. It should be understood that risk assessments are limited by what is known at a given point in time. In a recent example, it was noted that the distribution of peaks on a column in the purification train showed differences after a process transfer from one site to another. Although it caused no difference in product functionality, the cause of the variability was sought. After investigation, the two sites were found to be using different sources for a media component. Further investigation showed that the two sources differed in their content of a trace metal ion, which was a cofactor for an enzyme whose activity could explain the differences in peak distribution. Continuous monitoring of processes and the use of techniques such as multivariate data analysis are prerequisites for continuous improvement and superior process performance.9–12

ACKNOWLEDGMENT

The authors would like to thank Jennifer Mercer, Amgen Inc., Thousand Oaks, CA, for her review of the manuscript and her helpful comments.

Anurag S. Rathore, PhD, is a biotech CMC consultant and a faculty member at the Indian Institute of Delhi, India, +91-9650770650,
. Rathore also is a member of BioPharm International's editorial advisory board. Duncan Low is a scientific executive director in process development at Amgen Inc., Thousand Oaks, CA.

REFERENCES

1. International Conference on Harmonization. Q9, Quality risk management. Geneva, Switzerland; 2005.

2. ASTM Standard E-2476. Standard guide for Risk Assessment and Risk Control as it Impacts the Design, Development, and Control of PAT Processes for Pharmaceutical Manufacture. ASTM International. West Conshohocken, PA; 2009.

3. Rathore AS, Winkle H. Quality by Design for pharmaceuticals: regulatory perspective and approach. Nature Biotechnol. 2009;27:26–34.

4. Rathore AS. A roadmap for implementation of Quality by Design (QbD) for biotechnology products. Trends Biotechnol. 2009 Sep;27(9):546–53.

5. Rathore AS. Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol. 2009 Dec;27(12):698–705.

6. CMC Biotech Working Group A-Mab: a Case Study in Bioprocess Development. 2009. Available from: http://www.ispe.org/cs/explore_by_topic/pqli_resources and http://www.casss.org/displaycommon.cfm?an=1&subarticlenbr=286.

7. Low D, Phillips J. 2009. Evolution and integration of Quality by Design and process analytical technology. In: Rathore AS, Mhatre R, editors. Quality by Design for biopharmaceuticals. Hoboken, NJ: Wiley Interscience; 2009. p. 255–86.

8. Toro A, Colon J, Melendez-Colon V, Rivera JH. Changes in raw material sources from suppliers. Bioprocess Int. 2010 Apr;8(4):50–5.

9. Kirdar AO, Chen G, Rathore AS. Combining near-infrared (NIR) spectroscopy and multivariate data analysis (MVDA) for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Progr. 2010;26:527–31.

10. Lanan M. QbD for raw materials. In: Rathore AS, Mhatre R, editors. Quality by Design for biopharmaceuticals. Hoboken, NJ: Wiley Interscience; 2009. p. 193-210.

11. Kirdar AO, Green KD, Rathore AS. Application of multivariate analysis for identification and resolution of a root cause for a bioprocessing application. Biotechnol Prog. 2008;24:720–6.

12. Rathore A, Johnson R, Yu O, Kirdar, A, Annamalai A, Ahuja S, et al. Applications of multivariate data analysis in biotech processing. BioPharm Int. 2007;20(10):130–4.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here